While PSA serves a valuable role in identifying early signs of PC and monitoring disease progression, the debate surrounding frequent testing or lowering the age requirement has become apparent due to concerns about potential overdiagnosis and unnecessary biopsies [8]. The gene discussed is KLK3; the disease is pachyonychia congenita.